You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Colorcon
McKinsey
Baxter
Mallinckrodt

Last Updated: February 21, 2020

DrugPatentWatch Database Preview

Patent: 8,591,943

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,591,943
Title:Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
Abstract: The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.
Inventor(s): Deng; Yongqi (Newton, MA), Sun; Binyuan (Chestnut Hill, MA), Zeng; Hongbo (Westford, MA), Richards; Matthew (Somerville, MA), Shipps, Jr.; Gerald W. (Stoneham, MA), Cheng; Cliff C. (Cambridge, MA), Zhao; Yinyan (Rockville, MD), McRiner; Andrew (Melrose, MA), Meng; Zhaoyang (Lansdale, PA), Nan; Yang (Lansdale, PA), Patel; Mehul F. (Willow Grove, PA), Wrona; Iwona E. (Sharon, MA), Reddy; Panduranga Adulla (Walpole, MA), Eklov; Brian M. (Kalamazoo, MI), Tang; Shuyi (Belmont, MA), Liu; Duan (Arlington, MA), Mandal; Amit K. (Shrewsbury, MA), Zhao; Lianyun (Blue Bell, PA), Siddiqui; M. Arshad (Newton, MA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:13/263,193
Patent Claims:see list of patent claims

Details for Patent 8,591,943

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2039-02-26 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2039-02-26 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2039-02-26 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
McKesson
Johnson and Johnson
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.